期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 22, 期 9, 页码 1081-1097出版社
INFORMA HEALTHCARE
DOI: 10.1517/13543776.2012.717615
关键词
casein kinase 2; CK2 inhibitors; protein kinase CK2
资金
- Italian Ministry for University and Research (MIUR) [FIRB RBNE03YA3L]
Introduction: CK2 is a pleiotropic, ubiquitous and constitutively active protein kinase, localized in both cytosolic and nuclear compartments, where it catalyzes the phosphorylation of hundreds of proteins. CK2 is generally described as a tetramer composed of two catalytic (alpha and/or alpha') and two regulatory subunits (beta), however, the free alpha/alpha' subunits are catalytically active by themselves. CK2 plays a key role in several physiological and pathological processes and has been connected to many neoplastic, inflammatory, autoimmune and infectious disorders. In the last 20 years, several inhibitors of CK2 have been discovered though only one of these, CX-4945, has recently entered into Phase II clinical trials as potential anticancer drug. Areas covered: The main objective of the present review is to describe the development of CK2 activity modulators over the years according to the timeline of their patent registration. Expert opinion: CK2 was discovered in 1954, but the first patent on CK2 modulators was deposited only 50 years later, in 2004. However, in the last 5 years an increasing number of patents on CK2 inhibitors have been registered, reflecting an increased interest in this kind of drug candidates and their possible therapeutic applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据